Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2021 5
2022 1
2023 3
2024 3
2025 3
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, Gibson K, Kaplan J, Lisk L, Navarra S, Parikh SV, Randhawa S, Solomons N, Huizinga RB. Rovin BH, et al. Lancet. 2021 May 29;397(10289):2070-2080. doi: 10.1016/S0140-6736(21)00578-X. Epub 2021 May 7. Lancet. 2021. PMID: 33971155 Clinical Trial.
BACKGROUND: Voclosporin, a novel calcineurin inhibitor approved for the treatment of adults with lupus nephritis, improved complete renal response rates in patients with lupus nephritis in a phase 2 trial. This study aimed to evaluate the effica …
BACKGROUND: Voclosporin, a novel calcineurin inhibitor approved for the treatment of adults with lupus nephritis, impro …
Safety and Efficacy of Long-Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial.
Saxena A, Ginzler EM, Gibson K, Satirapoj B, Santillán AEZ, Levchenko O, Navarra S, Atsumi T, Yasuda S, Chavez-Perez NN, Arriens C, Parikh SV, Caster DJ, Birardi V, Randhawa S, Lisk L, Huizinga RB, Teng YKO. Saxena A, et al. Arthritis Rheumatol. 2024 Jan;76(1):59-67. doi: 10.1002/art.42657. Epub 2023 Sep 15. Arthritis Rheumatol. 2024. PMID: 37466424
OBJECTIVE: AURORA 2 evaluated the long-term safety, tolerability, and efficacy of voclosporin compared to placebo in patients with lupus nephritis (LN) receiving an additional two years of treatment following completion of the one-year AURORA 1 …
OBJECTIVE: AURORA 2 evaluated the long-term safety, tolerability, and efficacy of voclosporin compared to placebo in patients …
Voclosporin for Lupus Nephritis: A #NephJC Editorial on AURORA.
Auguste B, Teakell J, Ullur AR, Topf JM, Hiremath S. Auguste B, et al. Kidney Med. 2021 Oct 22;3(6):889-892. doi: 10.1016/j.xkme.2021.10.001. eCollection 2021 Nov-Dec. Kidney Med. 2021. PMID: 34938997 Free PMC article. No abstract available.
Journal Club: Efficacy and Safety of Voclosporin Versus Placebo for Lupus Nephritis (AURORA 1): A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Phase 3 Trial.
Rubio J, Kyttaris V. Rubio J, et al. ACR Open Rheumatol. 2021 Dec;3(12):827-831. doi: 10.1002/acr2.11338. Epub 2021 Aug 31. ACR Open Rheumatol. 2021. PMID: 34463434 Free PMC article. Review.
OBJECTIVE: Voclosporin, a novel calcineurin inhibitor approved for the treatment of adults with lupus nephritis (LN), improved complete renal response rates in patients with LN in a phase 2 trial. ...The adverse event profile was balanced between the two grou …
OBJECTIVE: Voclosporin, a novel calcineurin inhibitor approved for the treatment of adults with lupus nephritis (LN), i …
Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis.
Arriens C, Teng YKO, Ginzler EM, Parikh SV, Askanase AD, Saxena A, Gibson K, Caster DJ, Atsumi T, Lisk L, Randhawa S, Gluck R, Solomons N, Huizinga RB. Arriens C, et al. Arthritis Care Res (Hoboken). 2023 Jul;75(7):1399-1408. doi: 10.1002/acr.25007. Epub 2023 Feb 12. Arthritis Care Res (Hoboken). 2023. PMID: 36039949 Clinical Trial.
OBJECTIVE: This integrated analysis evaluates the efficacy and safety of voclosporin, a novel calcineurin inhibitor, at 23.7 mg twice daily in combination with mycophenolate mofetil (MMF) and oral glucocorticoids in lupus nephritis (LN) using pooled data from …
OBJECTIVE: This integrated analysis evaluates the efficacy and safety of voclosporin, a novel calcineurin inhibitor, at 23.7 mg twice …
Effect of Long-Term Voclosporin Treatment on Renal Histology in Patients With Active Lupus Nephritis With Repeat Renal Biopsies.
Rovin BH, Cassol C, Parikh SV, Saxena A, Solomons N, Birardi V, Yap E, Abner CW, Jayne DRW, Huizinga RB. Rovin BH, et al. Arthritis Rheumatol. 2025 Oct;77(10):1387-1393. doi: 10.1002/art.43209. Epub 2025 Jul 17. Arthritis Rheumatol. 2025. PMID: 40317902 Free PMC article. Clinical Trial.
OBJECTIVE: This study characterized the impact of voclosporin on kidney histology in patients with lupus nephritis (LN) who had protocolized repeat kidney biopsies in the AURORA clinical trials. ...These data are reassuring and further contribute to th …
OBJECTIVE: This study characterized the impact of voclosporin on kidney histology in patients with lupus nephritis (LN) …
Voclosporin: Unique Chemistry, Pharmacology and Toxicity Profile, and Possible Options for Implementation into the Management of Lupus Nephritis.
Kale A, Shelke V, Lei Y, Gaikwad AB, Anders HJ. Kale A, et al. Cells. 2023 Oct 11;12(20):2440. doi: 10.3390/cells12202440. Cells. 2023. PMID: 37887284 Free PMC article. Review.
VOC demonstrated efficacy superior to standard-of-care in controlling active lupus nephritis in the phase 2 AURA-LV and the phase 3 AURORA-1 trials and was approved for the treatment of active lupus nephritis. However, how to implement VOC into …
VOC demonstrated efficacy superior to standard-of-care in controlling active lupus nephritis in the phase 2 AURA-LV and the ph …
Evaluating the cost-effectiveness of voclosporin for the treatment of lupus nephritis in the United States.
Kennedy L, Lee E, Flauto R, Atencio V, Birardi V. Kennedy L, et al. J Manag Care Spec Pharm. 2024 Aug;30(8):773-781. doi: 10.18553/jmcp.2024.23324. Epub 2024 May 8. J Manag Care Spec Pharm. 2024. PMID: 38717044 Free PMC article.
BACKGROUND: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus; up to 30% of patients with LN will develop end-stage kidney disease (ESKD). ...The AURORA 2 study showed long-term efficacy and safety of voclosporin ove …
BACKGROUND: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus; up to 30% of patients with …
B-cell depletion or belimumab or voclosporin for lupus nephritis?
Lei Y, Loutan J, Anders HJ. Lei Y, et al. Curr Opin Nephrol Hypertens. 2021 Mar 1;30(2):237-244. doi: 10.1097/MNH.0000000000000662. Curr Opin Nephrol Hypertens. 2021. PMID: 33186226 Review.
PURPOSE OF REVIEW: Despite ground-breaking innovations for most autoimmune diseases, the treatment of lupus nephritis has remained largely the same for decades because none of the tested drugs demonstrated superiority over standard-of-care in randomized controlled c …
PURPOSE OF REVIEW: Despite ground-breaking innovations for most autoimmune diseases, the treatment of lupus nephritis has rema …
17 results